Apellis Pharmaceuticals, Inc. (APLS)
Pharmaceutical Preparations
Latest Price
$41.03
TTM P/E
37.64
Normalized P/E
--
Div Yield
--
Book Value
3.25
P/B Ratio
12.63
Valuation metrics
adjust assumptions →EPS: $0.20
Book value / share: $2.92
Formula: √(22.5 × EPS × BVPS)
Graham Number
$3.63
91% downside
EPS: $0.20
Target P/E: 38×
Formula: EPS × P/E
P/E Fair Value
$7.60
81% downside
Institutional Ownership
100.0% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13.54M | $544.0M | 10.58% | +7.28M | 2026-03-31 |
| Avoro Capital Advisors LLC | 12.22M | $491.0M | 9.55% | -- | 2026-03-31 |
| MORGAN STANLEY | 10.04M | $404.0M | 7.85% | +869.4K | 2026-03-31 |
| STATE STREET CORP | 6.84M | $275.0M | 5.35% | +2.23M | 2026-03-31 |
| UBS Group AG | 6.21M | $249.0M | 4.85% | +2.02M | 2026-03-31 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.40M | $217.0M | 4.22% | -- | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.77M | $191.0M | 3.73% | -- | 2026-03-31 |
| Deep Track Capital, LP | 4.53M | $182.0M | 3.54% | -3.22M | 2026-03-31 |
| Point72 Asset Management, L.P. | 4.18M | $168.0M | 3.27% | +3.59M | 2026-03-31 |
| RTW INVESTMENTS, LP | 3.69M | $148.0M | 2.88% | -3.98M | 2026-03-31 |